Genovis establishes subsidiary in the US

Genovis is establishing a wholly owned subsidiary headquartered in Cambridge,
Massachusetts, USA, to increase its presence in the North American market.
The subsidiary will sell all of the parent company's products on the North
American market, which today represents 60 percent of Genovis’ total sales.
Customers include the major pharmaceutical companies, which use the products to
screen new drug substances and for quality control in development and production
of new antibody-based drugs. The subsidiary will be headed by John M. Lindsay
and Philip Onigman, both of whom have extensive experience in sales and business
development in the Life Science market.

“We are now pursuing our strategy and establishing a presence with direct sales
in our largest market. Proximity to customers, accessible and skilled support, a
local warehouse and efficient deliveries are important cornerstones of our
offering. We are very pleased to have John Lindsay and Philip Onigman join us in
our US operations. Both are well-established and have extensive experience in
our industry. We look forward to an exciting and successful collaboration,” says
Sarah Fredriksson, CEO Genovis

John M Lindsay

John began his career at Millipore Corporation and quickly advanced to executive
vice president and business area manager of several divisions of the company. In
2000 John founded SciPartners, with the objective of building a platform for
development of early European companies and brands in North America. John’s
focus is the Life Science market, and over the past 14 years he has successfully
built up sales and marketing that led to rapid growth and increased revenues for
many companies.

Philip Onigman

Philip is principal and founder of Grand Street Consulting, specializing in
marketing for the Biotechnology Industry. Philip earned a BS in
Microbilogy/Biochemistry from the University of New Hampshire, and worked in
clinical and research laboratories at Massachusetts General Hospital and Tufts
Medical Center. Philip has served in commercialization and business
development roles including Technical Support, Market Development, Product
Management and Sales at Millipore, Lionbridge Technologies, GTC BioTherapeutics
and AdvanDx.
For more information, please contact: Sarah Fredriksson, CEO, Genovis AB Tel: 46
(0)46 -101235 sarah.fredriksson@genovis.com
ABOUT GENOVIS

Genovis’ business concept is to develop, produce and market innovative
technologies that facilitate and enable development of new treatment methods and
diagnostics for customers in the medical device and pharmaceutical industries.
The Group consists of Genovis AB and the subsidiary GeccoDots AB. Genovis
develops and sells unique enzymes in innovative product formats that facilitate
development and quality control of and biological drugs. GeccoDots uses
nanotechnology to produce a new type of contrast agent that is used in medical
imaging.

Genovis shares are listed on NASDAQ Stockholm First North, and Consensus is
Certified Adviser for the Company, t: 46 (0)31-745 50 00